Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTIS trial in diffuse systemic sclerosis
NL-OMON23346Phase 3Recruiting
- Sponsor
- EBMT
- Start
- Mar 2001
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide, antithymocyte globulin rabbit, filgrastim and autologous hematopoietic stem cells in systemic sclerosis (SSc) (2 arms), sponsored by EBMT. Primary endpoint: Event-free survival. Started Mar 2001; status: recruiting.
02
Drugs
cyclophosphamideantithymocyte globulin rabbitfilgrastimautologous hematopoietic stem cells
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON23346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23346.